Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
TOKYO, Nov 7, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) in Asia (9 countries/regions*) to a subsidiary of DKSH Holding Ltd.In our Asia and Latin America Pharmaceuticals Business (ALA Region…
Read More
0